Mineralys Therapeutics (MLYS) to Repurchase Potential Royalties for Lorundrostat

Article excerpt

Mineralys Therapeutics announced plans to repurchase potential royalties tied to Lorundrostat, its experimental treatment for a rare endocrine disorder. The deal allows the company to regain financial upside from the drug if it reaches commercial success, reversing an earlier monetization of those future payments. The move signals management confidence in the therapy's prospects as it advances through clinical development. Lorundrostat targets a narrow patient population but addresses an unmet medical need with limited treatment options.